SCHEMBL20102455

SCHEMBL20102455

CCOc1ccc2c(c1F)-c1c-2cc(C2CCCCCC2)c(F)c1F

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 9/20 0.39
APOBEC3G Q9HC16 2/20 0.36
PTGDR Q13258 4/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 2/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
CAMKK1 Q8N5S9 1/20 0.35
CAMKK2 Q96RR4 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM1A O60341 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20111583 1.00 PTGDR2 (0.39) PTGDR2APOBEC3GPTGDRALDH1A1HPGD
SCHEMBL20102450 0.99 PTGDR2 (0.37) PTGDR2APOBEC3GPTGDRALDH1A1HPGD
SCHEMBL20102451 0.96 ALOX5AP (0.36) PTGDR2ALOX5APFEN1CAMKK1CAMKK2
SCHEMBL20102453 0.93 KDM1A (0.36) PTGDR2APOBEC3GALDH1A1HPGDTSHR
SCHEMBL20111344 0.90 PTGDR2 (0.32) PTGDR2APOBEC3GPTGDRALDH1A1HPGD
SCHEMBL20111581 0.89 PTGDR2 (0.37) PTGDR2APOBEC3GPTGDRALDH1A1HPGD
SCHEMBL20117597 0.89 ALDH1A1 (0.34) ALDH1A1KDM1A
SCHEMBL20102454 0.88 HTR1D (0.38) PTGDR2PTGDRALOX5APFEN1
SCHEMBL20111610 0.86 KDM1A (0.33) PTGDR2APOBEC3GALDH1A1HPGDTSHR
SCHEMBL20111290 0.86 PTGDR2 (0.37) PTGDR2APOBEC3GPTGDRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2019-06-18 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed
EP-3315583-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC Corporation (JP) 2018-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S PTGDR2 1255/4885APOBEC3G 942/4885PTGDR 1618/4885
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device YBX1, PIEZO1, C1S PTGDR2 1255/4885APOBEC3G 942/4885PTGDR 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.